Altered proteasomal function in sporadic Parkinson's disease

Experimental Neurology

Volumn 179, Issue 1, 2003, Pages 38-46

  McNaught, Kevin St P ^a   Belizaire, Roger ^b   Isacson, Ole ^b   Jenner, Peter ^c   Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MCLEAN HOSPITAL   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aggresome; Lewy body inclusion; PA28; PA700; Parkinson's disease (PD); Substantia nigra pars compacta (SNc); Ubiquitin proteasome system; synuclein

Indexed keywords

20S PROTEOSOME; 26S PROTEOSOME; PROTEOME; UBIQUITIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BETA CHAIN; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 0037227397     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.8050     Document Type: Article

References (42)

1. Forno, L. S. 1996. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55: 259-272.
2. Pollanen, M. S., D. W. Dickson, and C. Bergeron. 1993. Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol. 52: 183-191.
3. Spillantini, M. G., R. A. Crowther, R. Jakes, et al. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95: 6469-6473.
4. Good, P. F., A. Hsu, P. Werner, et al. 1998. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57: 338-342.
5. Giasson, B. I., J. E. Duda, I. V. Murray, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989.
6. Alam, Z. I., S. E. Daniel, A. J. Lees, et al. 1997. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69: 1326-139.
7. Yoritaka, A., N. Hattori, K. Uchida, et al. 1996. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93: 2696-2701.
8. Lopiano, L., M. Fasano, S. Giraudo, et al. 2000. Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation. Neurochem. Int. 37: 331-336.
9. McNaught, K. S., C. W. Olanow, B. Halliwell, et al. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nature Rev. Neurosci. 2: 589-594.
10. Voges, D., P. Zwickl, and W. Baumeister. The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68: 1015-1068.
11. Sherman, M. Y., and A. L. Goldberg. 2001. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 29: 15-32.
12. Shimura, H., M. G. Schlossmacher, N. Hattori, et al. 2001. Ubiquitination of a new form of α-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 293: 263-269.
13. Leroy, E., R. Boyer, G. Auburger, et al. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452.
14. Polymeropoulos, M. H., C. Lavedan, E. Leroy, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
15. Kruger, R., W. Kuhn, T. Muller, et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genet. 18: 106-108.
16. Spira, P. J., D. M. Sharpe, G. Halliday, et al. 2001. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49: 313-319.
17. Bennett, M. C., J. F. Bishop, Y. Leng, et al. 1999. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274: 33855-33858.
18. Tofaris, G. K., R. Layfield, and M. G. Spillantini. 2001. Alpha-Synuclein metabolism and aggregation is linged to ubiqutin-independent degradation by the proteasome. FEBS Lett. 25504: 1-5.
19. Rideout, H. J., K. E. Larsen, D. Sulzer, and L. Stefanis. 2001. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78: 899-908.
20. Goedert, M. 2001. Alpha-synuclein and neurodegenerative diseases. Nature Rev. Neurosci. 2: 492-501.
21. Tanaka, Y., S. Engelender, S. Igarashi, et al. 2001. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10: 919-926.
22. Stefanis, L., K. E. Larsen, H. J. Rideout, et al. 2001. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21: 9549-9560.
23. Craiu, A., M. Gaczynska, T. Akopian, et al. 1997. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272: 13437-13445.
24. Noda, C., N. Tanahashi, N. Shimbara, et al. 2000. Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats. Biochem. Biophys. Res. Commun. 277: 348-354.
25. Hendil, K. B., R. Hartmann-Petersen, and K. Tanaka. 2002. 26[?]S Proteasomes function as stable entities. J. Mol. Biol. 315: 627-636.
26. Schmidt, T., K. S. Lindenberg, A. Krebs, et al. 2002. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: Redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann. Neurol. 51: 302-310.
27. Ii, K., H. Ito, K. Tanaka, and A. Hirano. 1997. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56: 125-131.
28. Jana, N. R., E. A. Zemskov, G. Wang, and N. Nukina. 2001. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10: 1049-1059.
29. Grune, T., T. Reinheckel, and K. J. Davies. 1996. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J. Biol. Chem. 271: 15504-15509.
30. Bulteau, A. L., K. C. Lundberg, K. M. Humphries, et al. 1999. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276: 30057-30063.
31. Touitou, R., J. Richardson, S. Bose, et al. 2001. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. EMBO J. 20: 2367-2375.
32. Davies, K. J. 2001. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83: 301-310.
33. Floor, E., and M. G. Wetzel. 1998. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70: 268-275.
34. Hirsch, E. C., B. Faucheux, P. Damier, et al. 1997. Neuronal vulnerability in Parkinson's disease. J. Neural Transm. Suppl. 50: 79-88.
35. El-Khodor, B. F., N. G. Kholodilov, O. Yarygina, and R. E. Burke. 2001. The expression of mRNAs for the proteasome complex is developmentally regulated in the rat mesencephalon. Brain Res. Dev. Brain Res. 129: 47-56.
36. Gibb, W. R., and A. J. Lees. 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51: 745-752.
37. Nam, S., D. M. Smith, and Q. P. Dou. 2001. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 276: 13322-13330.
38. Jenner, P., and C. W. Olanow. 1998. Understanding cell death in Parkinson's disease. Ann. Neurol. 44: S72-S84.
39. Schapira, A. H., V. M. Mann, J. M. Cooper, et al. 1990. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55: 2142-2145.
40. Canu, N., C. Barbato, M. T. Ciotti, et al. 2000. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J. Neurosci. 20: 589-599.
41. McNaught, K. S. P., C. Mytilineou, R. JnoBaptiste, et al. 2002. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81: 301-306.
42. McNaught, K. S. P., L. M. Bjorklund, R. Belizaire, et al. 2002. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. NeuroReport 13: 1437-1441.